However, long-term ADT treatment may significantly increase the amount of fat and circulating insulin levels.174 In prostate cancer (PCa) patients due to severe testosterone deficiency, resulting in significant insulin resistance and hyperglycemia, as well as increased diabetes and metabolic syndrome risk.175–177 Therefore, it is suggested that PCa patients receiving ADT treatment make lifestyle changes in order to prevent insulin resistance and metabolic syndrome. This evidence concerns the gene INS and metabolic syndrome.